|
Aug 7
|
Coherus Oncology (CHRS) Reports Q2 Loss, Beats Revenue Estimates
|
|
Aug 7
|
Coherus Oncology: Q2 Earnings Snapshot
|
|
Aug 7
|
Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update
|
|
Aug 6
|
Intas Pharmaceuticals and Accord BioPharma Become One of the Largest Global Suppliers of Pegfilgrastim with Acquisition of UDENYCA®
|
|
Aug 6
|
Coherus Oncology, Inc. (NASDAQ:CHRS) is largely controlled by institutional shareholders who own 54% of the company
|
|
Jul 31
|
Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025
|
|
Jun 25
|
Strength Seen in Krystal Biotech (KRYS): Can Its 4.2% Jump Turn into More Strength?
|
|
May 14
|
Coherus BioSciences First Quarter 2025 Earnings: Misses Expectations
|
|
May 13
|
Q1 2025 Coherus BioSciences Inc Earnings Call
|
|
May 13
|
Coherus BioSciences Inc (CHRS) Q1 2025 Earnings Call Highlights: Strategic Growth and ...
|
|
May 12
|
Coherus BioSciences (CHRS) Reports Q1 Loss, Lags Revenue Estimates
|
|
May 12
|
Coherus BioSciences: Q1 Earnings Snapshot
|
|
May 12
|
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
|
|
May 5
|
Coherus to Report First Quarter 2025 Financial Results on May 12, 2025
|
|
May 1
|
Coherus to Participate in Upcoming Investor Conferences
|
|
Feb 12
|
Coherus BioSciences, Inc. (CHRS): A Bull Case Theory
|
|
Sep 28
|
Coherus BioSciences, Inc. (CHRS): Worst 52-Week Low Stock to Buy Now
|
|
Sep 25
|
Short Interest Surges to 21.83% as Coherus BioSciences, Inc. (CHRS) Faces Revenue Challenges
|
|
Jun 27
|
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
|
|
May 11
|
Coherus BioSciences First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|